A daily tablet is emerging as one of the most credible challengers yet to the injectable weight-loss drugs that reshaped the market. In a 52-week phase 3 trial, an experimental once-daily pill called orforglipron delivered better blood-sugar control and more weight loss than the leading oral version of semaglutide, the drug sold as Ozempic and Wegovy in its injectable form. From a baseline average HbA1c of 8.3%, orforglipron cut that measure by roughly 1.71% to 1.91%, compared with 1.47% for oral semaglutide.
Why an oral GLP-1 pill matters
Semaglutide belongs to a class of medications known as GLP-1 receptor agonists, which mimic a gut hormone released after eating. That hormone signals fullness to the brain, slows digestion and prompts the release of insulin, and the drugs have proven highly effective for managing type 2 diabetes and promoting weight loss. Their main drawback has been the delivery method: the best-known versions must be injected into the belly, thigh or upper arm, a barrier for people with needle phobia or who simply find self-injection inconvenient.
Injectable GLP-1 drugs also require refrigeration throughout the supply chain, a logistical hurdle in low- and middle-income countries where cold-chain infrastructure is unreliable. Those constraints are why developers have pushed toward oral versions. An existing oral semaglutide works, but it must be taken on an empty stomach, users have to wait 30 minutes before eating or drinking, and it has poor bioavailability — only about 1% of the ingested drug is absorbed.
Orforglipron, developed by Eli Lilly, is designed to sidestep several of those problems. It belongs to a newer category called small-molecule drugs, meaning it is a synthetic compound small enough to be absorbed directly through the gut wall while still acting on GLP-1 receptors. Because it is not a peptide that closely resembles the natural hormone, it is cheaper and simpler to manufacture, and like oral semaglutide it does not require refrigeration.
What the trial actually found
The trial involved 1,698 adults with type 2 diabetes across six countries, and it set out to compare orforglipron against currently available oral semaglutide products. The primary measure was the reduction in HbA1c, a blood test reflecting average blood sugar over roughly three months; diabetes is defined as an HbA1c of 6.5% or higher. Orforglipron not only matched oral semaglutide, it proved superior for lowering blood sugar, according to the phase 3 results published in The Lancet.
Participants taking orforglipron also lost more weight — an average of 6.1 kg to 8.2 kg, compared with 5.3 kg for those on semaglutide. No head-to-head trial has compared orforglipron directly against injectable GLP-1 drugs, so its standing versus the injectables remains an open question. Researchers note the weight loss seen here is broadly comparable to what has previously been observed with injectables, but that is an inference rather than a direct comparison.
The trade-off showed up in tolerability. GLP-1 drugs commonly cause gastrointestinal side effects such as nausea, vomiting, diarrhea and constipation. In this trial, about 59% of participants on orforglipron reported such symptoms, compared with 37% to 45% on semaglutide, a difference the researchers attribute to the pill’s more pronounced daily peaks in drug concentration. Roughly 10% of orforglipron participants discontinued treatment because of adverse effects, versus 4% to 5% of those on semaglutide.
What it means for patients and the market
For people weighing options, the results suggest orforglipron could offer stronger blood-sugar and weight benefits than the oral semaglutide already on pharmacy shelves, without the injections or refrigeration that come with the older drugs. Its lower manufacturing cost could also matter for access, particularly in places where the cold chain is a problem. But the higher rate of side effects and the greater share of patients who stopped treatment are real considerations, because long-term adherence tends to be shaped as much by tolerability as by raw efficacy.
Several important questions remain unanswered from this trial alone. Orforglipron was tested here in people with type 2 diabetes, and it is still undergoing separate trials in people who have obesity but not diabetes, so its performance in that broader population has not yet been established. Pricing, regulatory approval timelines and how it will stack up against injectables in everyday use are also not settled by these data. Anyone considering a GLP-1 medication should discuss the choice with a clinician rather than assume one option is uniformly better, since the right fit depends on individual tolerance, cost and goals.
The near-term takeaway is that the oral weight-loss field is getting more competitive, which historically tends to expand choices for patients. Watch for the obesity trial results and any regulatory filings, which will determine whether orforglipron becomes a widely available alternative or remains a promising contender still working through the pipeline.
More from Morning Overview
- The NSA issues an urgent warning to all phone users about a setting most people leave on
- 5,000-year-old wolves on remote island upend domestication theory
- Scientists may have found a Type II civilization
- EPA finally kills ‘stupid feature’ in 60% of U.S. cars after 14 years of driver rage
*This article was researched with the help of AI, with human editors creating the final content.
